Research library

B

grade

Teduglutide may help reduce the need for Home Parenteral Nutrition in some patients with Short Bowel Syndrome, but more research is needed to confirm its benefits.

Median time of HPN for eight patients alive was 173 months.

summary

D

grade

Not reported in abstract.

Not reported in abstract.

summary

B

grade

Teduglutide may show promise in improving intestinal symptoms in a pediatric patient with refractory GI-GVHD, but further studies are needed to confirm its effectiveness.

Not reported in abstract.

summary

C

grade

Teduglutide may prevent metabolic dysfunction caused by antipsychotics in mice, but more research is needed to determine its relevance to humans.

Not reported in abstract.

summary

B

grade

This study highlights the potential for personalized drug screening in gastroenteropancreatic neuroendocrine neoplasms, although the clinical implications of the findings require further investigation.

Not reported in abstract.

summary

B

grade

Teduglutide may enable patients with severe short bowel syndrome to stop parenteral nutrition and improve their gastrointestinal symptoms, but this is based on a single case report.

Stool frequency decreased to 3-5 times per day after 4 months of teduglutide treatment.

summary

B

grade

Teduglutide may reduce the need for parenteral support in children with intestinal failure, but attention to nutritional status is essential due to observed declines in weight and BMI.

Mean percent reduction in parenteral calories was 49.5% by 3 years.

summary